Wendy Winckler | Executive Director, Next Generation Diagnostics
Novartis

Wendy Winckler, Executive Director, Next Generation Diagnostics, Novartis

Wendy Winckler joined NIBR in late 2012 as the Executive Director, Next Generation Diagnostics.  She and her group are applying cutting edge technologies such as next generation sequencing to characterize the molecular alterations in patient tumors and understand how these genetic changes correlate with therapy.  Prior to joining Novartis, Dr. Winckler was the Director of the Genetic Analysis Platform at the Broad Institute of MIT and Harvard. In that role, she led the Broad’s high-throughput SNP genotyping, gene expression, and directed sequencing laboratory, associated informatics and project management.  She was also co-principal investigator for the Broad’s center in the NIH Common Fund Genotype-Tissue Expression Project.  Dr. Winckler began research at the Whitehead Institute/MIT Center for Genome Research (now part of the Broad Institute) in 2001 and worked there in various leadership positions including project manager for cancer genomics, scientist for The Cancer Genome Atlas project, and assistant director of the Genetic Analysis Platform.  Winckler earned a B.Sc. in microbiology and molecular genetics from the University of California, Los Angeles, and a Ph.D. in genetics from Harvard University.

back to speakers